This work demonstrates optimized thymol nanoemulsions improve antimicrobial activity against MRSA, suggesting potential in treating multidrug-resistant infections.
The emergence of methicillin-resistant Staphylococcus aureus (MRSA) necessitates the development of novel antimicrobial strategies. This study developed and optimized thymol-loaded nanoemulsions (TNE) as a standardized, reproducible alternative to variable essential oil formulations using central composite design. The optimal formulation comprised 4.6% oil phase, 18.5% surfactant, and 2.5:1 surfactant-to-cosurfactant ratio, yielding nanoemulsions with particle size of 25.51 ± 0.15 nm, polydispersity index (PDI) of 0.114 ± 0.008, and zeta potential of − 2.73 ± 0.12 mV. TNE demonstrated consistent antimicrobial activity with MIC values of 15 mg/mL against MRSA and other bacterial strains. Comprehensive mechanistic studies using five complementary assays revealed that TNE exerts antimicrobial effects through multiple membrane-targeting pathways, including membrane permeabilization, depolarization, hydrophobicity alteration, and rigidity modulation. The multi-target mechanism suggests reduced likelihood of resistance development compared to conventional single-target antibiotics. These findings demonstrate that systematically optimized thymol nanoemulsions represent a promising standardized platform for combating multidrug-resistant infections, offering enhanced stability, controlled release characteristics, and reduced resistance potential.
No takes yet. Share an insight, caveat, or question.
Song et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: